Anavex Life Sciences

AVXL · Nasdaq · United States

Share price · AVXL

$0.72-2.48 (-77.52%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AVXL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 17 Nov 2026-9.5%
  2. 16 Nov 2026-12.4%
  3. 5 Oct 2026-9.6%
  4. 30 Sep 2026-14.4%
  5. 26 Aug 2026-9.0%
  6. 25 Aug 2026+14.5%
  7. 3 Aug 2026+7.3%
  8. 25 Mar 2026-34.6%
  9. 23 Mar 2026+9.4%
  10. 3 Dec 2025+24.5%

Share of unusual movement by asset

For each asset, the share of AVXL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Blarcamesine
events and moves
922%
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—69%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2/3
Sigma-1 receptor / muscarinic receptor (dual)Small molecule
Alzheimer's Disease
Phase 2
Sigma-1 receptor / muscarinic receptor (dual)Small molecule
Schizophrenia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
November 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-11-24 · Fiscal period ending 2026-09-30
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 March 2026WithdrawalBlarcamesineEU marketing authorisation application for blarcamesine withdrawn after a negative CHMP opinion
EU, EMA · Anavex Germany GmbH · Source ↗
11 December 2025Advisory committeeBlarcamesineCHMP negative opinion: EMA recommends refusing the blarcamesine marketing authorisation
EU, EMA · EMA (CHMP) · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2——$118M—-$9.1M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$4.2M$127M$5.3M-$4.4M operating cash flowreport ↗
2025-Q4—$4.7M$132M$5.7M-$7.2M operating cash flowreport ↗
2025-Q2—$10.0M$101M$13M-$12M operating cash flowreport ↗
2025-Q1—$9.9M$116M$11M-$5.9M operating cash flowreport ↗
2024-Q4—$10M$121M$12M-$12M operating cash flowreport ↗
2024-Q2—$12M$139M$12M-$5.2M operating cash flowreport ↗
2024-Q1—$9.7M$139M$11M-$12M operating cash flowreport ↗
2023-Q4—$8.7M$144M$8.6M-$7.3M operating cash flowreport ↗
2023-Q2—$10M$155M$11M-$7.7M operating cash flowreport ↗
2023-Q1—$11M$153M$13M-$8.5M operating cash flowreport ↗
2022-Q4—$12M$144M$13M-$5.8M operating cash flowreport ↗
2022-Q2—$9.3M$153M$12M-$7.0M operating cash flowreport ↗
2022-Q1—$8.6M$153M$10M-$9.6M operating cash flowreport ↗
2021-Q4—$8.7M$151M$11M-$3.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$38M$103M$12M-$39M operating cash flowreport ↗

Anavex Life Sciences reported fiscal 2025 results with revenue not disclosed, R&D spend of $37.59M, down 10.2% YoY, and cash and cash equivalents of $102.58M. The company posted a net loss of $46.38M for the year.

Management guided to an approximate cash runway of more than 3 years at the current cash utilization rate. Blarcamesine received a negative trend vote from the CHMP on its European Marketing Authorisation Application, and the company intends to request a re-examination. ANAVEX3-71 met its primary safety endpoint in a placebo-controlled Phase 2 schizophrenia study, with encouraging trends in secondary and exploratory analyses. The company also highlighted upcoming regulatory and clinical trial updates across its pipeline, including early Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and a Phase 2/3 design for Fragile X, along with recent peer-reviewed publications and planned conference presentations.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$42M$132M$11M-$31M operating cash flowreport ↗
2023-FY—$44M$151M$12M-$28M operating cash flowreport ↗
2022-FY—$38M$149M$12M-$24M operating cash flowreport ↗
2021-FY—$33M$152M$9.5M-$30M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Paeger Axel · directorAward / grant (derivative)50,000——Form 4
2026-11-03Kellmeyer Terrie · director, President and CEOAward / grant (derivative)200,000——Form 4
2026-11-03Donhauser Peter D.O. · directorAward / grant (derivative)50,000——Form 4
2026-11-03Velden Claus Vander · directorAward / grant (derivative)50,000——Form 4
2026-09-24Boenisch Sandra · PFO & TreasurerAward / grant (derivative)20,000——Form 4
2026-09-24Boenisch Sandra · PFO & TreasurerAward / grant (derivative)25,000——Form 4
2026-09-24Boenisch Sandra · PFO & TreasurerAward / grant (derivative)25,000——Form 4
2026-09-24Boenisch Sandra · PFO & TreasurerAward / grant (derivative)25,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 188 reporting institutions held 39.6M shares ($118.8M, 42.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.7,609,618$23.4M
2STATE STREET CORP4,512,028$13.9M
3VANGUARD CAPITAL MANAGEMENT LLC3,863,950$11.9M
4TWO SIGMA INVESTMENTS, LP3,247,888$10.0M
5GEODE CAPITAL MANAGEMENT, LLC2,188,275$6.7M
6SUSQUEHANNA INTERNATIONAL GROUP, LLP995,663$3.1M
7Summit Financial, LLC940,455$2.9M
8BANK OF AMERICA CORP /DE/863,150$2.6M
9GOLDMAN SACHS GROUP INC804,435$2.5M
10VANGUARD PORTFOLIO MANAGEMENT LLC783,148$2.4M
11AQR CAPITAL MANAGEMENT LLC756,792$2.3M
12CHARLES SCHWAB INVESTMENT MANAGEMENT INC756,558$2.3M
13NORTHERN TRUST CORP725,187$2.2M
14JANE STREET GROUP, LLC725,003$2.2M
15VANGUARD FIDUCIARY TRUST CO647,169$2.0M